Answers are grounded in this paper and cite their sources.
This research finds that kaempferol reduces bone loss in osteoporosis, indicating its potential as a therapeutic agent.
PURPOSE: This study aimed to investigate the effects and underlying mechanism of kaempferol (Kae) on osteogenic differentiation through 5-methylcytosine (m5C) modification in bone metabolism. MATERIALS AND METHODS: . The effects of Kae (5, 10, and 20 μM) on osteogenic differentiation were evaluated. m5C levels in MC3T3-E1 cells were measured by m5C dot blot assay, and the expression of several m5C-related genes was detected. The binding between Kae and an m5C-related gene was examined, and the interaction between NSUN2 andBMP2 was assessed. To investigate the regulatory role of Kae in osteoporosis, an ovariectomy (OVX)-induced osteoporotic mouse model was established. CONCLUSIONS: and ameliorates bone loss in OVX-induced osteoporotic mice. Kae binds to NSUN2 to mediate RNA m5C modification of BMP2 during osteogenic differentiation. Kae may be a promising therapeutic agent for osteoporosis.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: